Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts (ChIP-seq dataset)

using ChIP-seq we examined Chromatin occupancy of the MLL-fusion complex members Menin and DOT1L after treatment with DOT1L methyltransferase inhibitors EPZ5676 and the novel compounds "compound 10" and "compound 11" as well as with the Menin-inhibitor VTP50469 in MOLM13 cells. Furthermore we used ChiP-seq to quantify the loss of H3K79me2 (histone mark deposited by DOT1L) after treatment with the DOT1L inhibitors EPZ5676 and "compound 10" in MOLM13 and RS4,11 cells. Menin and DOT1L occupancy after treatment with DOT1L inhibitors and a Menin-inhibitor was assessed 4d after treatment with the drugs in MOLM13 cells via ChIP sequencing. Deposition of the histone mark H3K79me2 was measured at days 3, 6 and 9 after DOT1L-inhibitor treatment in MOLM13 and RS4,11 cells. For the analysis and normalization of the H3K79me2 ChIPseq we used drosophila spike-in (dm6 spike-in).